The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Akero Therapeutics Inc (NASDAQ: AKRO) closed at $54.36 up 0.02% from its previous closing price of $54.35. In other words, the price has increased by $0.02 from its previous closing price. On the day, 0.64 million shares were traded. AKRO stock price reached its highest trading level at $54.44 during the session, while it also had its lowest trading level at $54.34.
Ratios:
For a deeper understanding of Akero Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.83 and its Current Ratio is at 15.83. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On August 04, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $76. BofA Securities Upgraded its Neutral to Buy on January 30, 2025, whereas the target price for the stock was revised from $35 to $63.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 10 ’25 when Cheng Andrew sold 30,000 shares for $53.98 per share. The transaction valued at 1,619,340 led to the insider holds 526,114 shares of the business.
Rolph Timothy sold 12,500 shares of AKRO for $576,001 on Oct 07 ’25. The Chief Scientific Officer now owns 166,571 shares after completing the transaction at $46.08 per share. On Oct 07 ’25, another insider, Timothy Rolph, who serves as the Officer of the company, bought 56,369 shares for $46.04 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 4474707456 and an Enterprise Value of 3737486592.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.40, which has changed by 0.6982193 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $21.34. The 50-Day Moving Average of the stock is 4.56%, while the 200-Day Moving Average is calculated to be 13.15%.
Shares Statistics:
For the past three months, AKRO has traded an average of 2.17M shares per day and 1150800 over the past ten days. A total of 80.15M shares are outstanding, with a floating share count of 73.00M. Insiders hold about 11.27% of the company’s shares, while institutions hold 103.48% stake in the company. Shares short for AKRO as of 1763078400 were 4323058 with a Short Ratio of 1.99, compared to 1760486400 on 5813966. Therefore, it implies a Short% of Shares Outstanding of 4323058 and a Short% of Float of 5.4.
Earnings Estimates
The market rating of Akero Therapeutics Inc (AKRO) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.01, with high estimates of -$0.95 and low estimates of -$1.12.
Analysts are recommending an EPS of between -$3.65 and -$4.23 for the fiscal current year, implying an average EPS of -$3.94. EPS for the following year is -$4.16, with 4.0 analysts recommending between -$3.98 and -$4.58.